Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-36 (canceled).

Claim 7 (previously presented). A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor wherein the Src family tyrosine kinase inhibitor is 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylphenylamino)-8*H*-pyrido[2,3-*d*]pyrimidine-7-one.

Claim 8 (canceled).

Claim 9 (currently amended). The method of claim 8 claim 7 wherein the 4-anilino-3-quinolinecarbonitrile inhibitor has the general Formula (I):

wherein R^1 is methyl or $-(CH_2)_n$ -Z; X^1 is F, Cl, Br, I, and methyl; X^2 is H, F, Cl, Br, I, and methyl; X^3 is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl, 4-(1-methylpiperzinyl), 4-(1-ethylpiperzinyl), 1-(cis-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, -NHCH₂CH₂-1-morpholinyl, and -N(CH₃)-CH₂CH₂-N(CH₃)₂.

Application No. 10/801,050 - - - - - 3

Claim 10 (original). The method of claim 9 wherein R^1 is $-(CH_2)_n$ -Z, wherein X^1 and X^2 are both chloro, X^3 is methoxy, n is 3 and Z is 4-morpholinyl.

Claim 11 (currently amended). The method of claim 8 claim 7 wherein the 4-anilino-3-quinolinecarbonitrile inhibitor is 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile.

Claim 12-40 (canceled).